Should I buy Dentsply Sirona (XRAY) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on Dentsply Sirona
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Stifel | 50 % | +12.6 % | 6 | $17 +100% |
| Jefferies | 80 % | +5.6 % | 5 | $20 +135% |
| Morgan Stanley | 38 % | -11.1 % | 16 | $23 +170% |
| UBS | 0 % | -20.7 % | 6 | $17 +100% |
| Barrington Research | 17 % | -25.5 % | 18 | $17 +100% |
| Evercore ISI Group | 20 % | -26.1 % | 5 | $15 +76% |
| Needham | 0 % | -41.0 % | 10 | $23 +170% |
| Credit Suisse | 67 % | +1.0 % | 6 | — |
✅ Reasons to believe
- Median price target $12, i.e. +41% from the current price ($9).
- The most reliable firm on XRAY, B of A Securities (100% hit rate, 3 scored calls), targets $17 (call made on February 19, 2026, maturing on February 19, 2027) (+100%) in its most recent call.
- Pays a dividend (2.9% yield) — regular income on top of potential upside.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 5 ratings, 3 are neutral and 1 is a sell.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on XRAY
Median target $12 (+41%) · 5 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Dentsply Sirona now?
We won't decide for you. The facts: 20% of analysts rate it a buy, median target $12 (+41%), and B of A Securities (most reliable on XRAY, 100%) targets $17. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Dentsply Sirona?
Not according to analysts: the median target ($12) is still +41% above the current price ($9) (most reliable on XRAY: B of A Securities, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Dentsply Sirona still worth investing in?
It depends on the gap between the price ($9) and its estimated value: analysts target $12 on median (+41%), with 20% buys (most reliable on XRAY: B of A Securities, 100%). Cross-check with their real reliability on XRAY and the cautions above. Information, not advice.
What's the main risk in buying XRAY?
The consensus is not unanimous: of 5 ratings, 3 are neutral and 1 is a sell.
→ Go deeper: the full Dentsply Sirona profile (consensus, analyst reliability, price target, performance).